NRIP - Top Stock PIck - Announce $1.2M contract

From: "Annie" <xmelgnug@web.de>
To: trainers@chebucto.ns.ca
Cc: training@chebucto.ns.ca, sales@chebucto.ns.ca
Date: Tue, 02 Mar 2004 15:02:44 +0100
Precedence: bulk
Return-Path: <trainers-mml-owner@chebucto.ns.ca>
Original-Recipient: rfc822;"| (cd /csuite/info/lists/trainers; /csuite/lib/arch2html)"

next message in archive
no next message in thread
previous message in archive
Index of Subjects

----ALT--RHCW94281306627560
Content-Type: text/plain; charset=us-ascii
Content-Transfer-Encoding: 8bit

lithology wistful keller knock 
etruscan convey discrepant satisfactory titanium 
legitimate torsion mosquito semblance dent cigarette 

----ALT--RHCW94281306627560
Content-Type: text/html; charset=us-ascii
Content-Transfer-Encoding: 8bit

<html>

<body bgcolor="#FAFCFE">

<p><b>$1.2M COntract for NRIP - This stock is going crazy - March Top Stock Pick<br>
**************************************************************************<br>
$1.2M COntract for NRIP - This stock is going crazy - March Top Stock Pick</b><br>
<br>
!!!!!!!!The Stock has VERY TIGHT FLOAT - ONLY 200 000 shares !!!!!!<br>
<br>
A few days ago NRIP reported January and February sales total more than <br>
$250,000.00, a 75% increase over the same period last year. <br>
<br>
<br>
*************************************************************************<br>
Congratulations to all members who took advantage of our February Stock Pick<br>
<br>
GETC - The stock was profiled at 18 cents and reached 98 cents on Friday<br>
*************************************************************************<br>
<br>
--------------------------------------------------<br>
The hottest stock for the FIRST week of March<br>
<br>
<b>NRIP - NRIP - NRIP - NRIP - NRIP</b><br>
<br>
++ Top March Trading Alert ++<br>
<br>
Company Profile<br>
Nutri Pharmaceuticals Research, Inc.<br>
Symbol: <b>NRIP</b><br>
Current Price: $0.70<br>
<br>
<b>ONCE AGAIN - The Stock has VERY TIGHT FLOAT - ABOUT 200 000 shares<br>
<br>
SPECULATIVE NEAR TERM TARGET PRICE - $2.7<br>
SPECULATIVE LONG TERM TARGET PRICE - $3.0</b><br>
<br>
<br>
<font color="#FF0000" size="5">A few Reasons to own NRIP</font><br>
<br>
- Feb 24, 2004 NRIP announced the substantial increase of O2P(TM) orders<br>
January and February sales total more than $250,000.00, a 75% increase <br>
over the same period last year.<br>
<br>
- Feb 27, 2004 NRIP.PK is pleased to announce a new open-ended contract to <br>
supply high concentrate natural Vitamin E O2PT (oil to powder) product <br>
to International Specialty Botanical Products, Inc. <br>
This agreement is valued at minimum 1.2 million dollars<br>
This agreement is valued at minimum 1.2 million dollars<br>
This agreement is valued at minimum 1.2 million dollars<br>
<br>
- Their Facilities include<br>
<br>
• In-house research and development allow tailored formulations to your
requirements <br>
• A granulator with a capacity of 500 kilos <br>
• A blender with a capacity of 800 kilos <br>
• 3 encapsulation machines capable of 75,000 capsules per hour<br>
• 4 tablet presses capable of a half million tablets per hour<br>
• Tablet coating is available<br>
• Transformation of liquids to powder (The O2P Process)<br>
• A complete bottling and packaging department<br>
<br>
<br>
-------------------READ READ READ----------------------<br>
Nutri Pharmaceuticals Research, Inc. Announces 1.2 Million Dollar Sale<br>
-------------------------------------------------------<br>
<br>
LAS VEGAS, Feb 27, 2004 (BUSINESS WIRE) -- Nutri Pharmaceuticals Research, Inc.
(Pink Sheets:NRIP.PK), is pleased to announce a new open-ended contract to
supply high concentrate natural Vitamin E O2PT (oil to powder) product to
International Specialty Botanical Products, Inc. The contract calls for the
monthly processing and shipment of two or more tons of Vitamin E powder. This
agreement, valued at minimum 1.2 million dollars, will be a significant addition
the company's yearly sales. <br>
<br>
&quot;This contract, together with the recently announced acceptance of Kenko
Corporation, of Tokyo, as our exclusive Japanese Distributor for the Company's
O2PT products should further strengthen the Company's bottom line,&quot; Said Godfrey
Yew, president and CEO of Nutri Pharmaceuticals Research. <br>
<br>
About Kenko: Kenco Corporation is a major Japanese manufacturer, distributor and
world-wide exporter of chemicals, allied products, pharmaceuticals and
supplementary nutrients. Last year it had global sales of 150 million dollars.
<br>
<br>
About Nutri Pharmaceuticals Research Inc.: Nutri Pharmaceuticals Research Inc.
is the world's leading processor of oil-to-powder. The company's proprietary O2P
process transforms most edible oils into a free-flowing powder form that
preserves more of the natural active components than other processes. Such
powdered oils have application and demand in the food ingredient, livestock
feeds, pet foods, nutraceutical, cosmetic and pesticide market sectors. We are
also a wholesale private label manufacturer of vitamins and health food
supplements. <br>
<br>
This press release contains &quot;forward-looking statements&quot; within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements can be
identified by the lead-in &quot;Looking Forward.&quot; These statements are not guarantees
of future performance and involve significant risks and uncertainties. Actual
results may vary materially from those in the forward-looking statements as a
result of the effectiveness of management's strategies and implementation
thereof. <br>
<br>
<br>
---------------<br>
Disclaimer<br>
---------------<br>
Please be advised that nothing within this email shall constitute a solicitation
or an offer to buy or sell any security mentioned herein. This newsletter is
neither a registered investment advisor nor affiliated with any broker or
dealer. All statements made are our express opinion only and should be treated
as such. We may own, buy and sell any securities mentioned at any time. This
report includes forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements may include terms as
&quot;expect&quot;, &quot;believe&quot;, &quot;may&quot;, &quot;will&quot;, &quot;move&quot;,&quot;undervalued&quot; and &quot;intend&quot; or similar
terms. This newsletter was paid $700 from third party to send this report.
PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN ANY PROFILED COMPANY. To be
removed from further emails send email to:go4now@china.com <br>
---------------------<br>
&nbsp;</p>

</body>

</html>

----ALT--RHCW94281306627560--

next message in archive
no next message in thread
previous message in archive
Index of Subjects